# Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT01302808** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Lung Cancer
- Metastatic Cancer

## Interventions

- **COMBINATION_PRODUCT:** Erlotinib plus Romidepsin (8 mg/m^2)
- **COMBINATION_PRODUCT:** Erlotinib plus Romidepsin (10 mg/m^2)
- **COMBINATION_PRODUCT:** Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis
- **COMBINATION_PRODUCT:** (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis

## Key facts

- **NCT ID:** NCT01302808
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302808, "Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01302808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*